92 research outputs found
Hepatitis C treatment in a district Hospital
Publicação sob a forma de PosterThe aim of this study was the characterization of patients with Hepatitis C (HCV) under treatment.
Patients included in this study were followed in a Portuguese District Hospital between January 2012 and September 2014, have received treatment for HCV and who had at least one infectiology consultation in this period. Data were collected from the hospital computer system, and patient´s data were collected anonymously, without patient identification. Data analysis was performed using SPSS v22.0.
Were included in this study 87 patients who met the inclusion criteria, 75% (n=65) were males and 25% (n=22) female, with a mean age of 45±10 years. Most patients included in this study were Portuguese, resident in the Hospital district and nearby districts. Patients were diagnosed with HCV with a mean age of 3311 years, were followed on average for 53.5 years in this Hospital, and were diagnosed with HCV on average 126.9 years ago.
Among these patients, 44% (n=38) had genotype 1, 2% (n=2) genotype 2, 17% (n=15) genotype 3, 13% (n=11) genotype 4 and 24% (n=21) with unknown genotype.
Most frequent treatment regimens used by patients included in the study were the association of pegylated interferon alfa 2b (100mcg/week) and ribavirin (1000 mg/day) (52%; n=45); pegylated interferon alpha 2a (180mcg/week) and ribavirin (1000 mg/day) (42%; n=36). Other associations were used but less frequently: pegylated interferon alfa 2a + ribavirin + boceprevir (2%; n=2); pegylated interferon alfa 2b + ribavirin + boceprevir (3%; n=3); and pegylated interferon alfa 2a + ribavirin + telaprevir (1%; n=1).
Among included patients, 55 (63%) have performed, to date, one treatment for HCV, 19 (22%) have performed two treatments for HCV (using two different regimens or by using the same regimen twice), 9 (10%) already underwent treatment three times, 3 (3%) already underwent treatment four times and only one patient (1%) has conducted five treatments for HCV.
Excluding patients who were receiving treatment at the time of data collection (September 2014), the average length of all other treatments performed by the patients was 82 months, and most (40%; n=51) of treatments performed by patients had a duration from 6 to 9 months.
From the results, the standard treatment for patients with HCV appears to be in accordance with the existing guidelines for the treatment of this pathology. In the future it would be advisable further analysis and extended to other hospitals to assess the degree of compliance with currently existing national guidelines for the treatment of this pathology.info:eu-repo/semantics/publishedVersio
Atualizações das guidelines da American Heart Association (AHA) em reanimação pediátrica
Abordam-se as principais mudanças nas diretrizes de 2020 da AHA para a ressuscitação cardiopulmonar (RCP), relativas à atuação em lactentes e crianças.info:eu-repo/semantics/publishedVersio
Epidemiologic Investigation of Foodborne Outbreaks in Pharmacies: A Pilot Study
Introduction: The analysis of Foodborne Outbreaks (FBO) investigation data provides knowledge
on food vehicles and contributive factors of human infections allowing their risk management.
However, FBO are commonly underreported and alternative sources of information may prove
useful.
Purpose:
To test the adequacy of Pharmacies as an information source to identify foods involved in FBO,
their confection type and acquisition place as well as the main symptoms and medicines taken.
Methods:
Application of a FBO epidemiologic investigation inquiry to individuals with FBD suggestive
symptoms that went to 249 Pharmacies all over Portugal looking for treatment, between 18th
August and 15th de November 2014. Descriptive statistical analysis of the results was performed
and absolute and relative frequencies measures of location and dispersion were calculated in the
program SAS version 9.1.
Results: From 270 validated inquiries collected online until 29 October, 72.9% of the individuals
went to the Pharmacy as the first health resort (average age 44.1 years), 56.3% individuals
reported moderate symptoms, namely diarrhea and 58.0% of individuals took anti-diarrheal. The
most frequent place of consumption of the suspect food was home (51.5 %), restaurants (22.9%)
and parties (13.4%) and the food was meat (21.6%) and vegetables (18.3%), mostly cooked.
About 67% of the individuals reported that an average of other 4.6 individuals has consumed the
same food and 29.6% of them showed the same symptoms.
Significance:
The findings are consistent with the Portuguese FBO investigation data reported to EFSA and
therefore indicate that Pharmacies can be a valuable source of information about FBO and also
support consumer food safety education in order to prevent FBO.QRE
Analysis of a 17.9 kb region from Saccharomyces cerevisiae chromosome VII reveals the presence of eight open reading frames, including BRF1 (TFIIIB70) and GCN5 genes
We report the nucleotide sequence of a 17,893 bp DNA segment from the right arm of Saccharomyces cerevisiae chromosome VII. This fragment begins at 482 kb from the centromere. The sequence includes the BRF1 gene, encoding TFIIIB70, the 5' portion of the GCN5 gene, an open reading frame (ORF) previously identified as ORF MGA1, whose translation product shows similarity to heat-shock transcription factors and five new ORFs. Among these, YGR250 encodes a polypeptide that harbours a domain present in several polyA binding proteins. YGR245 is similar to a putative Schizosaccharomyces pombe gene, YGR248 shows significant similarity with three ORFs of S. cerevisiae situated on different chromosomes, while the remaining two ORFs, YGR247 and YGR251, do not show significant similarity to sequences present in databases
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P=0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P=0.003, and 42% vs. 16%, P= 2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those re-ceiving tisa-cel. Efficacy was not significantly different between both products
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P =0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P =0.003, and 42% vs. 16%, P <0.001, respectively). Infections in the first 6 months post-infusion were also more common in patients treated with axi-cel (38% vs. 25%, P =0.033). Non-relapse mortality was not significantly different between the axi-cel and tisa-cel groups (7% and 4%, respectively, P =0.298). With a median follow-up of 9.2 months, median PFS and OS were 5.9 and 3 months, and 13.9 and 11.2 months for axi-cel and tisa-cel, respectively. The 12-month PFS and OS for axi-cel and tisa-cel were 41% and 33% (P =0.195), 51% and 47% (P =0.191), respectively. Factors associated with lower OS in the multivariate analysis were increased lactate dehydrogenase, ECOG ≥2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those receiving tisa-cel. Efficacy was not significantly different between both products
HPV infection and p53 and p16 expression in esophageal cancer: are they prognostic factors?
Background: Esophageal squamous cell carcinoma (ESCC) is a highly lethal malignant tumor. Currently, Human papillomavirus (HPV) is suggested as a potential risk factor for esophageal cancer (EC) in addition to the classic risk factors, alcohol and tobacco, but this hypothesis still remains contradictory. We sought to investigate wether HPV and well-known biomarkers (p16 and p53) and patient-related factors that may have impact on survival of ESCC.
Methods: We conducted a prospective cohort study. By using multiplex PCR, we determined the prevalence of high risk HPV in ESCC, and evaluated the immunohistochemical expression of p16 and p53, molecular markers related to esophageal carcinogenesis in order to verify the potential influence of these variables in patients's survival. Survival rates were estimated using Kaplan-Meier methods. A multivariate confirmatory model was performed using Cox proportional hazards regression.
Results: Twelve (13.8%) of 87 patients were HPV-DNA positive. Positive reactions of p16 and p53 were 10.7% and 68.6%, respectively. Kaplan-Meier analysis indicated that men (p = 0.025) had poor specific-cancer survival and a shorter progression-free survival (p = 0.050) as compared to women; III or IV clinical stage (p < 0.019) had poor specific-cancer survival and a shorter progression-free survival (p < 0.001) compared to I and II clinical stage; not submitted to surgery (< 0.001) and not submitted to chemoradiotherapy (p = 0.039) had a poor specific-cancer survival, as well. The multivariate analysis showed that HPV, p16 and p53 status are not predictive parameters of progression-free and specific-cancer survival.
Conclusion: HPV infection and p53 and p16 expression are not prognostic factors in ESCC.CNPq Universal for providing supplies to the largest study, of which this
study is a part of, entitled “The role of human papillomavirus (HPV) as the
etiologic agent of esophageal cancer. A cross-sectional study, case-control
and longitudinal at Barretos Cancer Hospital”; (Grant number 482666/2012–9
to ALF); INCT HPV [Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) [Grant number 08/57889–1 to LLV]; Conselho Nacional de
Desenvolvimento Científico e Tencnológico (CNPq) (Grant number 573799/
2008–3 to LLV)].info:eu-repo/semantics/publishedVersio
A low-cost HPV immunochromatographic assay to detect high-grade cervical intraepithelial neoplasia
Objective
To evaluate the reproducibility and accuracy of the HPV16/18-E6 test.
Methods
The study population was comprised of 448 women with a previously abnormal Pap who were referred to the Barretos Cancer Hospital (Brazil) for diagnosis and treatment. Two cervical samples were collected immediately before colposcopy, one for the hr-HPV-DNA test and cytology and the other for the HPV16/18-E6 test using high-affinity monoclonal antibodies (mAb). Women with a histologic diagnosis of cervical intraepithelial neoplasia grade 2 or 3 were considered to be positive cases. Different strategies using a combination of screening methods (HPV-DNA) and triage tests (cytology and HPV16/18-E6) were also examined and compared.
Results
The HPV16/18-E6 test exhibited a lower positivity rate compared with the HPV-DNA test (19.0% vs. 29.3%, p<0.001) and a moderate/high agreement (kappa = 0.68, 95% CI: 0.60-0.75). It also exhibited a significantly lower sensitivity for CIN2+ and CIN3+ detection compared to the HPV-DNA test and a significantly higher specificity. The HPV16/18-E6 test was no different from cytology in terms of sensitivity, but it exhibited a significantly higher specificity in comparison to ASCH+. A triage test after HPV-DNA detection using the HPV16/18-E6 test exhibited a significantly higher specificity compared with a triage test of ASCH+ to CIN2+ (91.8% vs. 87.4%, p = 0.04) and CIN3+ (88.6% vs. 84.0%, p = 0.05).
Conclusion
The HPV16/18-E6 test exhibited moderate/high agreement with the HPV-DNA test but lower sensitivity and higher specificity for the detection of CIN2+ and CIN3+. In addition, its performance was quite similar to cytology, but because of the structural design addressed for the detection of HPV16/18-E6 protein, the test can miss some CIN2/3+ lesions caused by other high-risk HPV types.Cancer Prevention Department, Center for the Researcher Support and Pathology Department of the Barretos Cancer Hospital. This study was supported by CNPq 573799/2008-3 and FAPESP 2008/57889-1info:eu-repo/semantics/publishedVersio
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
Purpose BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown.
Patients and Methods A combined clinical and genetic institutional study of patients with PLGGs with long-term follow-up was performed (N = 510). Clinical and treatment data of patients with BRAF V600E mutated PLGG (n = 99) were compared with a large international independent cohort of patients with BRAF V600E mutated-PLGG (n = 180).
Results BRAF V600E mutation was detected in 69 of 405 patients (17%) with PLGG across a broad spectrum of histologies and sites, including midline locations, which are not often routinely biopsied in clinical practice. Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively ( P \u3c .001). Additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E PLGG. A similar independent role for CDKN2A and resection on outcome were observed in the independent cohort. Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG.
Conclusion BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current adjuvant therapy
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas
Purpose BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and Methods A combined clinical and genetic institutional study of patients with PLGGs with long-term follow-up was performed (N = 510). Clinical and treatment data of patients with BRAF V600E mutated PLGG (n = 99) were compared with a large international independent cohort of patients with BRAF V600E mutated-PLGG (n = 180). Results BRAF V600E mutation was detected in 69 of 405 patients (17%) with PLGG across a broad spectrum of histologies and sites, including midline locations, which are not often routinely biopsied in clinical practice. Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively (P < .001). Additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E PLGG. A similar independent role for CDKN2A and resection on outcome were observed in the independent cohort. Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG. Conclusion BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current adjuvant therapy. (C) 2017 by American Society of Clinical Oncolog
- …